Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Embecta Corp (EMBC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: EMBC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -27.55% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 734.24M USD | Price to earnings Ratio 12.76 | 1Y Target Price 22 |
Price to earnings Ratio 12.76 | 1Y Target Price 22 | ||
Volume (30-day avg) 656090 | Beta 1.21 | 52 Weeks Range 9.53 - 21.08 | Updated Date 04/2/2025 |
52 Weeks Range 9.53 - 21.08 | Updated Date 04/2/2025 | ||
Dividends yield (FY) 4.75% | Basic EPS (TTM) 0.99 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 5.25% | Operating Margin (TTM) 21.42% |
Management Effectiveness
Return on Assets (TTM) 3.13% | Return on Equity (TTM) - |
Valuation
Trailing PE 12.76 | Forward PE - | Enterprise Value 2101637901 | Price to Sales(TTM) 0.66 |
Enterprise Value 2101637901 | Price to Sales(TTM) 0.66 | ||
Enterprise Value to Revenue 1.9 | Enterprise Value to EBITDA 11.64 | Shares Outstanding 58134400 | Shares Floating 54434759 |
Shares Outstanding 58134400 | Shares Floating 54434759 | ||
Percent Insiders 0.47 | Percent Institutions 98.48 |
Analyst Ratings
Rating 3.5 | Target Price 21.05 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold 3 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Embecta Corp
Company Overview
History and Background
Embecta Corp. (EMBC) was spun off from Becton Dickinson (BDX) in April 2022, becoming an independent company focused solely on diabetes care. It was founded to concentrate on the development, manufacturing, and sale of diabetes injection devices.
Core Business Areas
- Diabetes Injection Devices: Embecta's primary business involves the development, manufacture, and sale of pen needles and syringes for insulin delivery.
Leadership and Structure
Devdatt (Dev) Kurdikar serves as the President and Chief Executive Officer. The company has a typical corporate structure with various departments reporting to the CEO.
Top Products and Market Share
Key Offerings
- Pen Needles: Embecta's pen needles are used with insulin pens for injecting insulin. Market share is estimated at around 25%. Competitors include Novo Nordisk and B. Braun.
- Syringes: Embecta manufactures syringes designed for insulin delivery. Their share in this market is estimated at around 15%. Competitors include Medtronic and Terumo Corporation.
Market Dynamics
Industry Overview
The diabetes care market is driven by the increasing prevalence of diabetes globally. The market is competitive, with various companies offering insulin delivery systems and related products.
Positioning
Embecta is a key player in the diabetes injection device market, with a focus on pen needles and syringes. Its competitive advantage lies in its focus on this specific market and its existing customer base from its time as part of Becton Dickinson.
Total Addressable Market (TAM)
The global diabetes devices market is expected to reach over $30 billion by 2027. Embecta's TAM is focused on the injection device segment, potentially 10-20% of the total market value.
Upturn SWOT Analysis
Strengths
- Focus on diabetes injection devices
- Established relationships with healthcare providers
- Spin-off allows for dedicated management focus
Weaknesses
- Relatively new independent company
- Concentrated product portfolio
- Dependence on insulin usage
Opportunities
- Expanding into new geographic markets
- Developing innovative injection technologies
- Partnering with insulin manufacturers
Threats
- Competition from established players
- Technological advancements in insulin delivery (e.g., pumps)
- Pricing pressures from healthcare providers
Competitors and Market Share
Key Competitors
- BDX
- NNIT
Competitive Landscape
Embecta benefits from its singular focus on diabetes injection devices, contrasting with larger, more diversified competitors like Becton Dickinson. However, this narrow focus also presents a vulnerability, as any downturn in the injection device market directly impacts Embecta.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth analysis requires several years of financial data and market performance. Data unavailable right now.
Future Projections: Future projections would be based on analyst estimates, which are not readily available without external financial data.
Recent Initiatives: Recent initiatives would include any product launches, partnerships, or strategic changes announced by the company.
Summary
Embecta Corp is a relatively new standalone company focused on diabetes injection devices, carved out from Becton Dickinson. Their focus presents both opportunities and challenges, as it allows for specialized management but also exposes them to market concentration risk. Their established relationships from before their spin-off offer them a competitive advantage. One thing the company needs to monitor is the innovation of diabetes care such as technology advancements in insulin delivery.
Similar Companies
BDX
Becton Dickinson and Company
BDX
Becton Dickinson and Company
Sources and Disclaimers
Data Sources:
- Company press releases
- Industry reports
- Financial news sources
Disclaimers:
This analysis is based on limited information and publicly available data. Financial metrics and projections are estimated and may not be accurate. Consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Embecta Corp
Exchange NASDAQ | Headquaters Parsippany, NJ, United States | ||
IPO Launch date 2022-04-01 | President, CEO & Director Mr. Devdatt Kurdikar Ph.D. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 2100 | Website https://www.embecta.com |
Full time employees 2100 | Website https://www.embecta.com | ||
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.